IFPMA’s 10 principles on counterfeit medicines
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) published its “Ten Principles on Counterfeit Medicines” to draw public attention to the issue.
The principles define counterfeit medicines, describe the threats they pose, suggest ways to prevent counterfeit drugs from reaching patients, and urge support for the World Health Organization (WHO) and its International Medical Products Anti-Counterfeiting Taskforce (IMPACT).
“Counterfeit medicines are a crime, and our industry is serious about tackling this problem head on,” said Haruo Naito, president of IFPMA and president and CEO of Eisai (Tokyo), in an IFPMA press release. Counterfeiters pose a threat to global public health by attempting to present their products as legitimate medicines, he added. “We stand ready to be an active partner in WHO-led efforts, including IMPACT.”
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents over 90 innovative pharmaceutical companies and associations around the world. Our industry’s almost three million employees discover, develop, and deliver medicines and vaccines that advance global health. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community improve the lives of people everywhere. For more information, visit ifpma.org.Learn more
Media ContactElliot Dunster firstname.lastname@example.org